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Objectives. To observe the choices of conventional disease modifying antirheumatic drugs (cDMARDs) and biologic DMARDs
(bDMARDs) in the management of rheumatoid arthritis (RA) in Australian routine clinical practice, to assess treatment survival
and determine the effect of cDMARDs/bDMARDs on disease activity. Methods. Routinely collected, deidentified clinical data
was sourced from 20 Australian rheumatology practices. RA patients aged ≥18 years, who had received cDMARDs/bDMARDs
and a recorded subsequent visit, were included. A linear mixed model was used to determine the change over time and the
percentage reduction in disease activity was summarized. Results. 12,526 RA patients were included: 72% females, mean age 62
years. cDMARDs and bDMARDs were used in 92% and 30% of patients, respectively. The most commonly prescribed cDMARD
was methotrexate (76% patients); median time to stopping treatment was 337 months [95% CI: 279–ND]. Etanercept was the most
commonly prescribed bDMARD (12% patients); median time to stopping treatment was 79 months [95% CI: 57–93]. Of 5,341
patients with a first change in medication (cDMARD or bDMARD), 87% had therapy escalation and 13% deescalation. Reduction
in DAS28-ESR, 6-month post-DMARDs initiation ranged from 3%, adalimumab, to 14%, leflunomide and tocilizumab.Conclusions.
In this largeAustralian cohort of unselected community RA patients, the choices of cDMARDs/bDMARDs are aligned with current
international guidelines.
1. Introduction
High-quality clinical research underpins our knowledge of
the efficacy of various rheumatoid arthritis (RA) therapies
[1–4]. Randomized clinical trials (RCTs) have provided reas-
suring safety and efficacy evidence to support the use of the
numerous new therapeutic options for RA over the last 20
years [1–3]. However, in real world practice, outside of the
controlled environment of these RCTs, additional factors are
likely to influence the use of conventional disease modifying
antirheumatic drugs (cDMARDs) and biologic DMARDs
(bDMARDs).
RCTs are conducted on carefully selected groups of
patients under strict clinical conditions; therefore, it is
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unclear how the efficacy and safety signals observed in the
RCTs will translate into the uncontrolled, relatively unse-
lected environment of routine clinical practice.
There are limited routine clinical practice data available
that assess the uptake of new treatments in RA patients [5, 6].
Such data would be useful to better understand any barriers
to the implementation of new evidence and would be likely to
inform strategies designed to enhance rational prescribing.
The OPAL-QUMI (Optimising Patient outcomes in Aus-
tralian rheumatoLogy-Quality Use of Medicines Initiative)
consortium [7] is a point of care-derived observational
registry database with clinical data recorded by Australian
rheumatologists in real-time during routine clinical encoun-
ters. Cross-sectional data from OPAL has helped to provide
insights into the reasons why a proportion of RA patients
remain in moderate disease activity using a treat-to-target
strategy [8].
2. Methods
2.1. Study Design. CEDAR is a multicentre, longitudinal,
observational study. The primary objective of the study
was to identify the choices of cDMARDs/bDMARDs being
made over time for the management of RA in Australian
patients. The secondary objectives were to assess the sur-
vival of RA patients on treatment and the effects of
cDMARDs/bDMARDs on disease activity.
The study which was approved by the University of New
South Wales Human Research Ethics Committee (reference
number HC12094) was conducted in accordance with local
guidelines, as set out in the National Statement on Ethical
Conduct in Human Research.
2.2. Inclusion Criteria. Patients diagnosed with RA, aged
≥ 18 years, who had received any medication, including
cDMARDs, bDMARDs, corticosteroids, or NSAIDs, either as
monotherapy or in addition to their stable previous therapy,
and who also had subsequent follow-up visits as well as a
change in cDMARDs/bDMARDs recorded were eligible to be
included in the study. Patients who requested their data not
to be collected for research purposes were excluded from the
analyses.
2.3. Data Capture. The study was conducted by the OPAL-
QUMI using the clinical software program Audit4 (described
previously) [7]. Deidentified data was sourced from 20
participating rheumatology practices comprising 42 rheuma-
tologists across Australia. Data was captured in May 2012.
For the assessment of treatment effect on disease activity, the
baseline data was collected inMay 2012 and 6-month data was
collected in November 2012.
2.4. Clinical Observations. Parameters collected included
demographics (gender and age), diagnosis (clinical onset
of RA and disease duration), disease measures (including
DAS28-ESR), tender joint count (TJC), swollen joint count
(SJC), and laboratory observations (inflammatory mark-
ers, autoantibody status, RF and/or ACPA positivity) and
medications (NSAIDs, steroids, cDMARDs and bDMARDs
with initiation dates, duration of treatment, and reason for
cessation).
However, being point of care clinical data, there are
parameters missing for some analyses (e.g., effect of treat-
ment on disease activity) in these cases; we have high-
lighted/defined the number of patients included.
2.5. Analytical Assessments and Statistical Considerations.
Medication change was analyzed in 9 prespecified categories:
methotrexate monotherapy, combination of >1 cDMARDs,
combination of methotrexate and leflunomide, monotherapy
of cDMARDs other than methotrexate, monotherapy of
bDMARDs, combination of bDMARDs plus methotrexate,
combination of bDMARDs plus cDMARDs other than
methotrexate, combination of bDMARDs and >1 cDMARDs,
and no cDMARDs/bDMARDs therapy. Treatment escala-
tion was defined as a new cDMARDs/bDMARDs being
introduced and treatment deescalation was defined as the
cessation of cDMARDs/bDMARDs.
Treatment survival was defined as the number of months
from the first prescription of the drug until the last known
date taking the drug. Survival on treatment was analyzed
for the most frequently recorded cDMARDs (methotrexate,
hydroxychloroquine, leflunomide, and sulfasalazine) and
bDMARDs (etanercept, adalimumab, tocilizumab, and abat-
acept). The number of patients on other biologics was too
small for any meaningful analyses to be carried out. Govern-
ment subsidized bDMARDs sequentially became available
in Australia for etanercept in 2003, adalimumab in 2004,
abatacept in 2008, and tocilizumab in 2010. Hence, data
for tocilizumab, in particular, was over a shorter timeframe
in this study. The EULAR response criteria were defined
according to van Gestel et al., 1996 [9].
Descriptive statistics [mean, standard deviation (SD), and
range] were provided for continuous variables and frequency
counts for categorical variables. The median and distribution
of treatment survival were estimated using Kaplan-Meier
methodology. A linear mixed model was used to determine
change over time and all medications with adequate sample
size were included. The assumptions of the linear mixed
model were that the observations are normally distributed
with a constant variance and independence. The assumptions
were assessed graphically.
3. Results
3.1. Patients. A total of 12,526 RA patients were screened:
72% females, mean age 62 years (range 18–100 years). Demo-
graphics and disease characteristics for the bDMARDs and
bDMARDs groups are presented in Table 1. There were 57%
of patients with a baseline DAS28-ESR measurement and
the mean score was 3.2 (SD 1.56). RF and ACPA positivity
rate was not available for the study; diagnosis of rheumatoid
arthritis was made by the treating rheumatologist.
3.2. Prescribed Medications. Ninety-two percent (𝑛 = 11,511)
of patients had at least one cDMARD, 30% (𝑛 = 3,697) had
at least one bDMARD, 58% (𝑛 =7,223) had an oral corticos-
teroid, and 30% (𝑛 = 3,699) had at least one NSAID (mainly
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Figure 1: Kaplan-Meier plot of treatment survival: (a) cDMARDs and (b) bDMARDs. ND = not determined.
Table 1: Patient demographics and disease characteristics.
𝑛 Mean SD Min–max
Age (years) 12,526 61.9 14.0 18.0–100.0
cDMARDs# 11,511 61.8 13.9 18.0–99.0
bDMARDs∗ 3,697 59.0 13.1 19.0–91.0
Disease duration (years) 9,069 11.1 10.6 0–77.4
cDMARDs 8,591 11.1 10.6 0–77.4
bDMARDs 2,387 13.7 10.5 0.3–61.1
DAS28-ESR 7,112 3.2 1.6 0–8.8
cDMARDs 6,728 3.2 1.6 0–8.8
bDMARDs 2,576 3.4 1.7 0–8.7
Tender joint count 8,842 3.6 5.6 0–28.0
cDMARDs 8,285 3.6 5.5 0–28.0
bDMARDs 3,057 4.4 6.3 0–28.0
Swollen joint count 8,842 3.6 5.5 0–28.0
cDMARDs 8,285 3.7 5.5 0–28.0
bDMARDs 3,057 4.2 6.1 0–28.0
Rheumatoid factor 4,115 137.4 297.5 0–5088.0
cDMARDs 3,846 139.4 300.0 0–5088.0
bDMARDs 1221 158.9 344.1 0–4886.0
ACPA 2282 110.5 198.3 0–2000.0
cDMARDs 2137 110.5 193.0 0–2000.0
bDMARDs 726 124.7 210.4 0–1816.0
SD = standard deviation; #patients taking at least one cDMARD; ∗patients
taking at least one bDMARD.
meloxicam and celecoxib). The most commonly prescribed
cDMARDs and bDMARDs were methotrexate (75.9%; 𝑛 =
9,508) and etanercept (12.3%; 𝑛 = 1,545), respectively, with all
prescribed cDMARDs and bDMARDs presented in Table 2.
3.3. Treatment Survival. The treatment survival curves are
presented in Figures 1(a) and 1(b). The median time to
stopping treatment was 337 months [95% CI: 279–ND] for
methotrexate, 152 months [95% CI: 120–168] for hydroxy-
chloroquine, 112 months [95% CI: 96–140] for sulfasalazine,
and 61 months [95% CI: 58–79] for leflunomide, while, for
patients receiving bDMARDs, the median time to stopping
treatment was 79 months [95% CI: 57–93] for etanercept, 68
months [95% CI: 58–ND] for adalimumab, and 47 months
[95% CI: 28–ND] for abatacept. The median time to stopping
tocilizumab was not reached at the time of data analysis.
For patients commencing cDMARDs, Kaplan-Meier (KM)
estimates show that 95% [95% CI: 94.5–95.5] of the patients
who commenced on methotrexate, 82% [95% CI: 80.7–83.6]
on hydroxychloroquine, 77% [95% CI: 75.0–78.2] on lefluno-
mide, and 82% [95% CI: 80.1–83.7] on sulfasalazine persisted
on the treatment at 12 months.
Similarly for bDMARDs, KM estimates show that 80%
[95% CI: 77.9–82.4] of patients who commenced on etaner-
cept, 81% [95% CI: 78.2–82.9] on adalimumab, 85% [95% CI:
81.5–88.0] on tocilizumab, and 75% [95% CI: 70.0–80.1] on
abatacept persisted on the treatment at 12 months.
3.4. Medication Choice over Time. A total of 5,341 patients
had a first change in medication after receiving their initial
RA medication. Of these, 4,660 (87%) had their treatment
escalated and 681 (13%) had their treatment deescalated.
The most common first therapeutic RA medication changes
were treatment escalations from monotherapy methotrex-
ate, monotherapy cDMARDs other than methotrexate, and
monotherapy bDMARDs (Figure 2(a)).
Two thousand one hundred and eighty-four patients
had a second change in their medication; 1,244 (57%)
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Figure 2: Most common treatment changes in RA medications at first and second change. (a) Treatment algorithm observed when DMARDs
were first changed. (b) Treatment algorithm observed when DMARDs were changed a second time. Boxed groups at the top of each figure
represent the patient’s medication group prior to the medication change. The lines lead to boxes beneath that represent the distribution of
medication groups after the medication change. Combo = combination; mono = monotherapy; MTX = methotrexate. Percentages may not
add up to 100% as only the most common changes are included.
had their treatment escalated and 940 (43%) had their
treatment deescalated. The most common treatment
changes in RA medications at a second change are
shown in Figure 2(b), which illustrates five of the most
common decisions (combination of more than one
cDMARD, methotrexate plus leflunomide, bDMARDs
plus methotrexate, combination of bDMARDs plus more
than one cDMARD, and cDMARDs other than methotrexate
plus bDMARDs).
3.5. Disease Activity. Over a 6-month period, the change in
disease activity was assessed following the commencement
of a DMARD. Statistically significant, although clinically
modest, reductions in mean DAS28-ESR were observed for
methotrexate (9.4%), hydroxychloroquine (9.6%), lefluno-
mide (13.8%), sulfasalazine (12.9%), etanercept (8.9%), and
tocilizumab (13.9%). A reduction in DAS28-ESR (3.4%)
was also observed with adalimumab; however, this was not
statistically significant (Table 3).
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Table 2: Distribution of treatments in the total patient cohort (𝑁 = 12,526). Multiple occurrences of the same medication in one individual
were counted once.
cDMARDs 𝑛 (%) bDMARDs 𝑛 (%)
Patients with at least one treatment 11,511 (91.9%) Patients with at least one treatment 3,697 (29.5%)
Methotrexate 9,508 (75.9%) Etanercept 1,545 (12.3%)
Hydroxychloroquine 3,527 (28.2%) Adalimumab 1,329 (10.6%)
Leflunomide 3,275 (26.1%) Tocilizumab 618 (4.9%)
Sulfasalazine 2,340 (18.7%) Abatacept 481 (3.8%)
Sodium aurothiomalate 114 (0.9%) Golimumab 376 (3.0%)
Azathioprine 98 (0.8%) Rituximab 339 (2.7%)
Cyclosporine 89 (0.7%) Certolizumab pegol 273 (2.2%)
Auranofin 43 (0.3%) Infliximab 68 (0.5%)
Penicillamine 28 (0.2%) Anakinra 3 (<1.0%)
Cyclophosphamide 10 (0.1%)
Table 3: Change in DAS28-ESR scores over a 6-month period.
Treatment
as monotherapy or in combination 𝑛
Month 0
mean (SEM)
Month 6
mean (SEM)
Change over time
value (%) 𝑃 value
Methotrexate 1,850 3.19 (0.03) 2.89 (0.03) 0.30 (9.4%) <0.001
Hydroxychloroquine 494 3.33 (0.06) 3.01 (0.06) 0.32 (9.6%) <0.001
Leflunomide 472 3.53 (0.07) 3.04 (0.06) 0.49 (13.8%) <0.001
Sulfasalazine 319 3.55 (0.09) 3.09 (0.08) 0.46 (12.9%) <0.001
Adalimumab 324 2.96 (0.07) 2.86 (0.06) 0.10 (3.4%) 0.106
Etanercept 394 3.15 (0.07) 2.87 (0.06) 0.28 (8.9%) <0.001
Tocilizumab 128 2.51 (0.112) 2.16 (0.10) 0.35 (13.9%) 0.001
EULAR responses at 6 months were analyzed for 9 med-
ications (as combination or monotherapy): methotrexate,
hydroxychloroquine, leflunomide, sulfasalazine, etanercept,
adalimumab, tocilizumab, abatacept, and rituximab, with the
remaining medications not having sufficient data to record a
EULAR response (Table 4).
4. Discussion
This study describes the use of cDMARDs/bDMARDs and
medication survival in a large cohort of unselected com-
munity RA patients. Conventional DMARD usage reflected
the contemporary treatment paradigm with methotrexate,
hydroxychloroquine, leflunomide, and sulfasalazine being
the predominant cDMARDs used. Over one-quarter of
patients in this study used leflunomide, which is a higher
rate of usage than what has been observed in Europe and
North America [10, 11]. This may be because leflunomide
is one of the cDMARD options listed for use prior to a
patient accessing government funded biologics in Australia.
For bDMARDs, almost 30% of Australian RA patients had
been exposed to at least one bDMARD with etanercept,
adalimumab, tocilizumab, and abatacept being the most
common.
Treatment survival was long for all the studied
cDMARDs. Methotrexate had the longest treatment survival
and appeared to be fulfilling a role as an anchor medication,
as it was also the most commonly used medication. The
median time on treatment was shorter for bDMARDs
compared to cDMARDs. This may be because, in Australia,
patients must fail to respond to at least 2 cDMARDs prior to
accessibility to government funded bDMARDs. Accordingly,
the patient group receiving bDMARDs in Australia are
selected as nonresponders and therefore may represent
a group with more refractory disease compared to the
unselected group of patients receiving cDMARDs. It is to be
expected that the response rates in this more refractory group
might therefore be reduced. Nevertheless, the bDMARD
median survival rates were similar to those seen in an Italian
registry cohort [12].
Australian rheumatologists appear to closely follow the
EULAR treatment guidelines for use of medications in the
treatment of RA [4]. At the first medication change in
patient treatment, the most common escalation pathway
was from monotherapy methotrexate. The most common
second medication change was the addition of a bDMARD
to the combination cDMARDs regimens. These pathways
are generally consistent with both the NICE and ACR
guidelines updated in 2013 and 2012, respectively [13, 14], with
the exception that, in OPAL patients, initial monotherapy
cDMARD treatment is considerably more common than
initial combination therapy.
The modest reductions in DAS28-ESR over 6 months
for the bDMARDs in the OPAL patient cohort appear to
be lower than what might have been expected based on
previously reported RCTs [15–18] and other observational
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studies [5, 6, 19–22]. There are a number of reasons why
this might be the case. For the RCTs the patient population
was selected with a high disease activity, while the published
observational studies had stricter selection criteria for the
patients in their analyses. In our study the average bDMARD
DAS28-ESR prior to medication changes was 3.4, which is
considerably lower than the average DAS28-ESR seen in
RCTs (often around 6.0) and observational registries (around
5.1–6.0) [5, 6, 15–21] using the same medications. A higher
starting DAS28 provides the opportunity for a larger fall
in DAS28 following the commencement of a medication,
and this may explain the differences between the OPAL
and other reported bDMARD responses. We were unable to
explain the observed lower baseline DAS28-ESR for patients
starting bDMARDS; presumably the treating rheumatologist
considered there was sufficient disease activity to warrant
commencement of biologic treatment.
There are limitations in the ability to make comparisons
between drugs in this study. Rather than being randomly
allocated, medications were selected based on individual
patient comorbidities and clinician perceptions of different
medication efficacy/risk profiles. In addition, Australian gov-
ernment rules, which restrict funding support for bDMARDs
until there is a documented failure to respond to at least 2
cDMARDs, may also play a role [2]. Because these and other
variables are not able to be controlled in this study design,
any outcome differences might be explained by differences in,
for example, disease severity/refractoriness being unequally
allocated in the treatment groups.
In conclusion, this longitudinal study in a large cohort
of unselected community-based RA patients from OPAL
clinics identified that medication choices in the Australian
rheumatology clinics were in keeping with international
guidelines. One exception was that there appeared to be
less use of initial combination cDMARDs therapy. Treatment
survival was long in all DMARDs groups studied. The first
RA medication changes were escalations from monother-
apy methotrexate, cDMARDs other than methotrexate, and
bDMARDs. Improvements in disease activity were seen in
all DMARDs studied. Initiation of cDMARDs/bDMARDs
was associated with disease activity reduction 6 months after
commencement of treatment.
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